zika
viru
zikv
remain
larg
quiescent
nearli
six
decad
first
appear
zikv
reappear
result
declar
intern
public
health
emerg
world
health
organ
time
zikv
consid
induc
mild
ill
establish
caus
sever
clinic
manifest
includ
fetal
anomali
neurolog
problem
autoimmun
disord
infect
pregnanc
caus
congenit
brain
abnorm
includ
microcephali
neurolog
degener
case
syndrom
make
infect
zikv
substanti
public
health
concern
genom
molecular
investig
underway
investig
zikv
patholog
recent
enhanc
pathogen
well
design
safe
potent
vaccin
drug
therapeut
review
describ
progress
design
develop
variou
antizikv
therapeut
includ
drug
target
viru
entri
cell
helicas
protein
nucleosid
inhibitor
protein
small
molecul
methyltransferas
inhibitor
interferon
repurpos
drug
drug
design
aid
comput
neutral
antibodi
convalesc
serum
antibodi
limit
antibodydepend
enhanc
herbal
medicin
addit
coval
inhibitor
viral
protein
express
antitolllik
receptor
molecul
discuss
counter
zikvassoci
diseas
need
make
rapid
progress
develop
novel
therapi
work
effectu
inhibit
zikv
zika
viru
zikv
mosquitoborn
viru
belong
spondweni
serocomplex
genu
flaviviru
famili
flavivirida
becom
new
threat
follow
ebola
viru
epidem
singh
et
al
expand
zikv
epidem
declar
emerg
world
health
organ
februari
fajardo
et
al
zikv
singlestrand
rna
viru
encod
singl
polyprotein
cleav
form
matur
protein
ie
capsid
envelop
e
precursor
membran
nonstructur
protein
flavivirus
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
close
relat
zikv
last
six
decad
sinc
discoveri
zikv
consid
mild
human
pathogen
recent
emerg
threat
global
health
show
increas
virul
rapid
spread
associ
microcephali
grave
neurolog
complic
like
syndrom
gb
caolormeau
et
al
carteaux
et
al
mlakar
et
al
sarno
et
al
zika
viru
wide
tissu
tropism
experiment
rhesu
macaqu
model
infect
hemolymphat
system
lymph
node
spleen
cardiopulmonari
gastrointestin
integu
genitourinari
tissu
along
adren
gland
spinal
cord
cerebrospin
fluid
coffey
et
al
addit
report
muscl
kidney
bladder
excret
urin
gourinat
et
al
male
zikv
infect
test
govero
et
al
prostat
semin
vesicl
explain
longterm
persist
viremia
semen
even
viru
longer
detect
blood
femal
reproduct
system
viru
maintain
vagina
uteru
hirsch
et
al
vagin
epithelium
mice
uterin
fibroblast
miner
diamond
miner
diamond
demonstr
wide
tissu
tropism
viru
hofbauer
cell
trophoblast
endotheli
cell
placenta
addit
zikv
found
infect
cornea
neurosensori
retina
optic
nerv
aqueou
humor
tear
zikv
infect
eye
result
uveiti
furtado
et
al
persist
viru
cerebrospin
fluid
lymph
node
appear
enhanc
activ
rapamycin
mtor
proinflammatori
antiapoptot
signal
pathway
reduc
extracellular
matrix
signal
aid
et
al
zika
viru
adapt
human
host
alter
codon
usag
facilit
viral
replic
increas
viral
titer
de
melo
freir
et
al
furthermor
zikv
placent
transfer
abil
infect
neuron
tissu
grow
fetus
evid
martin
et
al
mlakar
et
al
complic
zikv
infect
intensifi
unavail
effect
prophylact
vaccin
therapeut
spread
zikv
earlier
limit
small
geograph
area
facilit
global
unplan
urban
poor
sanit
inadequ
health
servic
emerg
insecticid
resist
mosquito
vector
mosquito
mainli
aed
aegypti
ae
albopictu
play
primari
role
zikv
transmiss
musso
gubler
addit
sexual
transmiss
maletofemal
femaletomal
maletomal
transmiss
report
hamer
et
al
mathemat
model
studi
conduct
gao
et
al
indic
sexual
activ
contribut
transmiss
typic
incub
period
day
despit
rel
low
viral
load
peopl
infect
human
patient
serv
sourc
zikv
foy
et
al
viremia
declin
convalesc
begin
time
person
longer
infecti
mosquito
howev
remain
infect
human
host
low
infect
rate
convalesc
stage
end
establish
long
last
immun
gao
et
al
zika
viru
vaccin
develop
includ
inactiv
viru
nucleic
acidbas
vaccin
dna
rna
live
vector
vaccin
subunit
vaccin
viruslik
particl
recombin
zikv
devast
effect
effect
therapeut
agent
vaccin
urgent
need
present
sever
drug
report
use
treat
zikv
repurpos
drug
effort
develop
effect
drug
increas
worldwid
compound
phase
trial
alam
et
al
ali
et
al
present
review
discuss
recent
advanc
prospect
design
develop
variou
antivir
drug
therapeut
zikv
infect
includ
identif
novel
drug
target
updat
inform
compil
contribut
design
develop
addit
effect
drug
pharmaceut
curtain
ill
effect
zikv
activ
innat
immun
system
virus
lead
releas
interferon
ifn
respons
elimin
virus
immun
regul
vitro
cell
cultur
system
develop
zikv
cultiv
shown
inhibit
viral
replic
contrera
arumugaswami
type
interferon
shown
dosedepend
inhibit
zikv
replic
cell
cultur
studi
use
quantit
rtpcr
goebel
et
al
invers
document
bowen
et
al
demonstr
zikv
abil
evad
presenc
type
interferon
respons
degrad
signal
molecul
trophoblast
cell
secret
exhibit
antivir
activ
singlestrand
rna
virus
vitro
model
condit
medium
obtain
pht
cell
found
inhibit
zikv
growth
trophoblast
nontrophoblast
cell
stimul
secret
bayer
et
al
inhibit
viral
entri
cell
serv
first
line
defens
zikv
infect
zikv
first
bind
cell
receptor
includ
axl
nowakowski
et
al
dcsign
tim
tam
hamel
et
al
enter
cell
clathrindepend
endocytosi
zikv
entri
sever
hamper
human
microgli
cell
line
silenc
clathrin
heavi
chain
compon
essenti
clathrinco
vesicl
format
gtpase
requir
pinch
endocyt
vesicl
plasma
membran
tim
receptor
mediat
viral
entri
bind
viral
phosphatidylserin
phosphatidylethanolamin
jemiel
et
al
entri
wnv
ebov
inhibit
duramycinbiotin
less
profound
hemolyt
effect
exhibit
cellular
cytotox
richard
et
al
receptor
also
involv
zikv
entri
therefor
drug
evalu
prevent
zikv
entri
peptid
gqasngvfvihwgkfdsfgiav
deriv
japanes
enceph
viru
jev
e
protein
stem
abl
prevent
zikv
infect
ic
even
nanomolar
scale
nm
also
decreas
viral
load
prevent
histopatholog
damag
brain
test
mous
attenu
inflammatori
respons
mode
entri
zikv
variou
drug
inhibit
viral
entri
replic
depict
figur
screen
molecul
abil
inhibit
zikv
replic
nanchangmycin
polyeth
obtain
streptomyc
nanchangensi
possess
insecticid
antibacteri
activ
shown
block
zikv
replic
cell
vitro
consid
act
target
axl
receptor
block
clathrinmedi
endocytosi
howev
exact
mechan
action
nanchangmycin
unknown
rausch
et
al
two
small
druglik
molecul
identifi
homolog
model
silico
report
inhibit
zikv
e
protein
bind
viral
receptor
antivir
activ
confirm
vitro
test
thu
viral
inhibitor
may
candid
molecul
zikv
drug
research
clinic
valid
fernando
et
al
fusion
endosom
lysosom
critic
step
releas
viru
endosom
obatoclax
potenti
antineoplast
proapoptot
synthet
small
molecul
inhibitor
mesyl
salt
report
reduc
acid
endolysosom
vesicl
vitro
model
antagonist
effect
virus
requir
low
ph
fusion
entri
zikv
wnv
yfv
other
despit
limit
obatoclax
work
broadspectrum
antivir
agent
varghes
et
al
howev
clinic
phase
ii
trial
treat
hematolog
myeloid
malign
obatoclax
produc
satisfactori
result
possibl
due
inadequ
inhibit
famili
protein
chloroquin
antimalari
drug
rais
endolysosom
ph
inhibit
zikv
infect
human
brain
microvascular
endotheli
cell
human
neural
stem
cell
mous
neurospher
delvecchio
et
al
similarli
saliph
molecul
preclin
studi
vatpas
inhibitor
test
inhibitor
endocytosi
obstruct
zikv
infect
adcock
et
al
griffithsin
lectin
isol
red
alga
griffithsia
sp
potent
flavivir
entri
inhibitor
crosslink
highmannos
oligosaccharid
present
viral
e
glycoprotein
shown
wide
antivir
activ
hiv
alexandr
et
al
hpv
levendoski
et
al
hsv
nixon
et
al
hcv
takeb
et
al
sar
okeef
et
al
squalamin
fda
approv
cation
chemic
act
disturb
electrostat
interact
viru
host
membran
fusion
bud
zasloff
et
al
found
well
toler
compon
eye
drop
clinic
studi
conduct
human
particip
therefor
potent
drug
use
antivir
agent
zikv
singlestrand
rna
genom
encod
polyprotein
proteolyt
cleav
three
structur
protein
c
prm
e
seven
nonstructur
protein
protein
rnadepend
rna
polymeras
play
import
role
viral
rna
synthesi
inhibit
ifn
signal
bind
grant
et
al
zikv
protein
exhibit
helicas
activ
essenti
viral
replic
helicas
domain
activ
triphosph
facilit
unwind
transloc
rna
time
replic
zikv
helicas
along
attract
target
zikv
drug
develop
small
membraneassoci
interferoninduc
transmembran
protein
ifitm
intrins
immun
system
defens
abl
inhibit
replic
sever
pathogen
virus
report
inhibit
earli
stage
infect
replic
zikv
hela
cell
predomin
role
play
savidi
et
al
cavinafungin
alaninalcontain
lipopeptid
fungal
origin
recent
found
inhibit
zikv
polyprotein
process
cleavag
host
protein
signal
peptid
inhibit
host
endoplasm
reticulum
signal
peptidas
vitro
model
estoppey
et
al
synthet
shown
inhibit
zikv
entri
host
vivo
assay
use
mous
rhesu
macaqu
model
li
et
al
vitro
studi
conduct
vero
cell
use
compound
ribavirin
show
favipiravir
abl
reduc
cell
death
caus
zikv
cai
et
al
thu
compound
inhibit
zikv
replic
cell
cultur
need
explor
use
safe
zikv
numer
drug
involv
inhibit
viru
replicationhav
portray
figur
positivesens
genom
ssrna
translat
polyprotein
cleav
structur
nonstructur
protein
replic
occur
surfac
endoplasm
reticulum
cytoplasm
viral
factori
dsrna
genom
synthes
genom
ssrna
viru
assembl
take
place
endoplasm
reticulum
endoplasm
reticulum
virion
bud
transport
golgi
apparatu
golgi
prm
protein
cleav
matur
virion
take
place
virion
releas
exocytosi
obatoclax
chloroquineinhibit
acid
environ
endolysosom
vesicl
squalamin
cation
chemic
disturb
electrostat
interact
viru
host
membran
fusion
bud
cavinafungin
alaninalcontain
lipopeptid
fungal
origin
inhibit
zikv
polyprotein
process
also
cleavag
signal
peptid
host
protein
nanchangmycin
polyeth
obtain
streptomyc
nanchangensi
small
druglik
molecul
block
receptor
thu
inhibit
zikv
entri
mediat
entri
inhibit
duramycinbiotin
flavivir
protein
two
major
catalyt
domain
first
domain
rnadepend
rna
polymeras
rdrp
second
one
methyltransferas
domain
egloff
et
al
conserv
region
zikv
mtase
rdrp
structur
identifi
current
antivir
target
region
flavivirus
like
denv
wnv
yfv
may
use
zikv
duan
et
al
also
involv
ifn
antagon
mutant
zikv
unabl
prevent
ifnstimul
signal
grow
ifndefici
cell
line
vaccin
potenti
structur
analysi
provid
inform
design
small
molecul
inhibitor
may
prevent
interferon
inhibit
dar
et
al
nucleosid
analog
may
incorpor
viral
nascent
rna
chain
rdrp
activ
caus
prematur
termin
rna
synthesi
kok
screen
librari
nucleosid
analog
cmethyl
nucleosid
found
effici
termin
synthesi
select
zikv
cytotox
advers
effect
cellular
prolifer
observ
nucleosid
target
activ
rdrp
site
rather
termin
elong
nascent
viral
rna
chain
anoth
nucleosid
analog
cmethyladenosin
develop
initi
hcv
replic
inhibitor
also
evalu
inhibit
zikv
replic
vero
cell
mous
model
use
mous
model
defici
receptor
strain
intraperiton
inocul
zikv
approxim
plaqueform
unit
pfu
anim
result
diseas
inocul
anim
treat
cmethyladenosin
dose
mgkgday
drug
delay
onset
viremia
virusinduc
morbid
mortal
infect
mice
zmurko
et
al
despit
demonstr
flavivir
two
major
catalyt
domain
rnadepend
rna
polymeras
rdrp
methyltransferas
domain
nucleosid
analog
like
cmethyl
nucleosid
cmethyladenosin
sofosbuvir
may
incorpor
polymeras
activ
rdrp
viral
nascent
rna
chain
caus
prematur
termin
rna
synthesi
bind
activ
site
methyltransferas
domain
respons
transfer
mrna
cap
sinefungin
adenosin
deriv
isol
streptomyc
griseoleu
inhibit
sam
natur
substrat
methyltransferas
inhibit
methyltransferas
activ
helicas
crystal
structur
reveal
conserv
triphosph
pocket
posit
charg
tunnel
accommod
rna
helicaseactiv
inhibit
presenc
dival
cation
due
extend
conform
adopt
condit
tetrapeptideboron
acid
potent
inhibitor
proteas
berberin
myricetin
epigallocatechingal
bind
affin
proteas
also
inhibit
zikv
replic
smallmolecul
inhibitor
inhibit
capsid
ribavirin
inhibit
host
inosin
monophosph
dehydrogenas
viral
polymeras
repurpos
drug
like
chloroquin
azithromycin
niclosomid
use
treat
zikv
infect
efficaci
anim
model
drug
remain
unsuccess
phase
clinic
trial
conduct
adenosin
analog
found
effect
flavivirus
includ
zikv
vitro
vivo
studi
exhibit
reduc
viremia
mice
deng
yq
et
al
unfortun
preclin
anim
test
found
toxic
suitabl
human
trial
sofosbuvir
sovaldi
nucleotid
analog
inhibitor
commerci
avail
treatment
chronic
hcv
infect
activ
metabolit
bind
activ
site
reznik
ashbi
also
shown
abil
inhibit
zikv
infect
human
tumor
cell
line
human
fetalderiv
neuron
stem
cell
bullardfeibelman
et
al
reznik
ashbi
clinic
phase
ii
studi
regimen
contain
sofosbuvir
found
clinic
safe
efficaci
mangia
piazzolla
class
b
drug
use
men
nonpregn
women
prevent
tissu
damag
cethynyl
cmethyl
analog
triphosph
found
incorpor
rdrp
zikv
therefor
effici
termin
elong
rna
chain
henc
may
candid
design
better
antivir
zikv
protein
contain
methyltransferas
respons
transfer
mrna
cap
methyltransferas
null
mutant
found
lethal
viru
target
methyltransferas
structur
domain
may
prevent
zikv
propag
structur
analysi
aid
identif
methyltransferas
inhibitor
base
silico
analysi
could
lead
identif
hotspot
drug
design
develop
antizikv
drug
coutard
et
al
stephen
et
al
furthermor
sinefungin
adenosin
deriv
origin
isol
streptomyc
griseoleu
potenti
antifung
antiparasit
compound
competit
inhibit
sam
natur
substrat
methyltransferas
well
methyltransferas
activ
basi
structur
comput
analysi
sinefungin
abl
attach
gtp
gdp
analog
might
use
enhanc
affin
toward
enzym
greater
select
inhibit
zikv
replic
hercik
et
al
sever
toxic
observ
drug
anim
studi
conduct
dog
goat
usag
antiparasit
agent
robertgero
et
al
hamper
clinic
use
therefor
less
toxic
better
toler
deriv
must
obtain
test
zikv
inhibitor
use
imped
zikv
infect
helicas
action
inhibit
dival
cation
caus
adopt
extend
conform
understand
interact
led
identif
small
molecul
inhibit
zikv
zikv
helicas
crystal
structur
reveal
conserv
triphosph
pocket
posit
charg
tunnel
accommod
rna
critic
substratebind
pocket
may
good
target
antivir
tian
et
al
report
helicas
zikv
close
relat
member
famili
flavivirida
therefor
drug
target
helicas
virus
could
also
explor
control
zikv
crystallograph
structur
proteas
zikv
indic
tetrapeptideboron
acid
would
potent
inhibitor
proteas
lei
et
al
base
studi
surfac
plasmon
reson
kinet
proteas
inhibit
lee
et
al
identifi
sever
small
molecular
inhibitor
proteas
addit
group
identifi
preopen
conform
zikv
proteas
xray
crystallograph
analysi
molecular
dock
analysi
reveal
berberin
fdaapprov
quaternari
ammonium
salt
use
denv
high
bind
affin
proteas
zikv
sahoo
et
al
hybrid
combinatori
substrat
librari
approach
also
use
determin
substrat
specif
proteas
design
phosphonatecontain
proteas
inhibitor
rut
et
al
lim
et
al
test
plant
polyphenol
compound
abil
inhibit
escherichia
coliexpress
zikv
proproteas
inhibit
proteas
activ
evalu
fluoresc
reson
energi
transferbas
assay
among
compound
test
myricetin
show
strongest
inhibit
proteas
follow
luteolin
epicatechin
gallat
gallocatechin
gallat
epigallocatechin
gallat
cap
peptidomimet
boronicacid
compound
found
form
zikv
proteas
inhibitor
complex
might
biolog
import
inhibit
zikv
replic
lei
et
al
structur
function
insight
gain
crystallograph
techniqu
acceler
discoveri
structurebas
antizikv
compound
nucleosid
biosynthesi
inhibitor
broad
antivir
activ
limit
number
compound
avail
clinic
use
inhibit
host
inosin
monophosph
dehydrogenas
impdh
viral
polymeras
key
antivir
activ
ribavirin
flavivirus
cranc
et
al
mycophenol
acid
mpa
impdh
inhibitor
exhibit
potent
dosedepend
anti
zikv
activ
ec
cell
cultur
experi
confirm
use
qrtpcr
goebel
et
al
contrari
find
adcock
et
al
found
mpa
effect
ec
observ
signific
cytotox
cytopathogen
effect
highthroughput
assay
dihydroorot
dehydrogenas
dhodh
host
enzym
respons
pyrimidin
biosynthesi
possibl
enzym
target
antivir
research
brequinar
inhibitor
enzym
exhibit
antizikv
activ
ec
half
maxim
effect
concentr
common
measur
drug
potenc
lower
ec
effect
drug
submicromolar
level
low
therapeut
index
brequinar
restrict
clinic
use
comparison
target
e
protein
capsid
gain
less
research
attent
dimer
protein
posit
charg
surfac
hydrophob
core
pocket
singl
smallmolecul
inhibitor
identifi
despit
poor
oral
bioavail
shown
decreas
viremia
viral
load
modoc
viru
yfv
hcv
screen
panel
chemic
divers
molecul
use
highthroughput
assay
nonmutagen
select
inhibit
flavivirus
byrd
et
al
mediat
selfinteract
capsid
protein
impos
structur
rigid
disturb
assembl
disassembl
denv
particl
scaturro
et
al
concept
capsid
protein
stabil
may
also
applic
zikv
clinic
studi
three
essenti
phase
research
highthroughput
comput
silico
drug
design
mediumthroughput
vitro
drug
test
lowthroughput
vivo
drug
test
basak
nandi
understand
zikv
structur
would
aid
design
antivir
therapi
curtail
zikv
infect
cox
et
al
found
block
mtase
rdrp
respect
base
comput
dock
analysi
ramharack
soliman
polymeras
inhibit
andrographolid
andrographi
wherea
bisabolol
levomenol
matricaria
recutita
myoporum
crassifolium
respect
block
proteas
virtual
screen
feranchuk
et
al
silico
techniqu
identifi
enzym
blocker
allow
simultan
assess
variou
compound
limit
financi
experiment
resourc
cost
virtual
screen
million
compound
mcule
databas
led
select
two
molecul
inhibit
constant
ki
valu
respect
onawol
et
al
openzika
ibm
world
commun
grid
project
use
identifi
drug
molecul
dock
variou
zikv
structur
platform
allow
data
share
research
worldwid
facilit
speedi
discoveri
antizikv
drug
ekin
et
al
elucid
therapeut
essenti
compon
like
sirna
mirna
sgrna
target
zikv
integr
multiom
platform
zikavr
avail
platform
offer
function
includ
wholegenom
align
codon
inform
bia
assess
phylogenet
deduct
inform
regard
glycosyl
site
primer
design
gupta
et
al
therapeut
base
enzym
nucleosid
capsid
inhibitor
current
infanc
much
work
need
carri
bring
clinic
ground
comput
analysi
allow
high
throughput
screen
potenti
activ
molecul
howev
vivo
valid
prior
requisit
move
bench
bedsid
drug
take
decad
develop
test
efficaci
safeti
sinc
present
approv
vaccin
drug
avail
zikv
major
focu
research
therefor
attempt
drug
repurpos
scientist
evalu
repurpos
sever
fda
approv
drug
zikv
infect
direct
promis
drug
candid
shortlist
adapt
variou
screen
methodolog
exampl
chloroquin
readili
increas
ph
acid
vesicl
akpovwa
inhibit
conform
chang
essenti
fusion
viru
envelop
endosom
membran
smit
et
al
vitro
studi
reveal
chloroquin
decreas
number
zikvinfect
neural
cell
differ
cell
model
protect
cellular
death
delvecchio
et
al
antimalari
drug
quinacrin
mefloquin
also
demonstr
antizikv
activ
inhibit
autophagi
balasubramanian
et
al
screen
librari
fdaapprov
drug
establish
antivir
like
bortezomib
mycophenol
acid
compound
previous
report
antivir
activ
eg
daptomycin
found
inhibit
zikv
replic
human
cervic
placent
neural
stem
primari
human
amniot
cell
barrow
et
al
screen
panel
compound
contain
fdaapprov
drug
drug
clinic
trial
pharmacolog
activ
compound
suppress
infectioninduc
caspas
activ
human
neural
progenitor
cell
glial
cell
infect
zikv
use
model
quantifi
zikvinduc
activ
http
bioinfoimtechresinmanojkzikavr
compound
procaspas
inhibitor
emricasan
success
protect
neural
cell
monolay
threedimension
organoid
cultur
neural
cell
decreas
zikvinduc
similarli
screen
fdaapprov
chemic
divers
compound
zikvinfect
cell
concentr
led
select
lovastatin
drug
use
reduc
cholesterol
use
cancer
treatment
broadspectrum
antimetabolit
palonosetron
use
treat
chemotherapyinduc
nausea
vomit
kitasamycin
macrolid
antibiot
select
criteria
includ
select
index
maximum
activ
ec
compound
pascoalino
et
al
niclosamid
clinic
given
treat
helminth
inefct
protect
zikvinfect
cell
inhibit
viru
replic
bortezomib
sorafenib
anticanc
drug
possess
antivir
activ
well
toler
phase
clinic
trial
azithromycin
commerci
avail
antibiot
also
found
inhibit
zikv
prolifer
cultur
brain
cell
suggest
possibl
drug
prevent
gb
microcephali
retallack
et
al
recent
bromocriptin
drug
indic
treatment
pituitari
tumor
parkinson
diseas
type
diabet
shown
inhibit
zikv
replic
vitro
possibl
occupi
activ
site
protein
fluorescencebas
enzymat
assay
also
reveal
bromocriptin
inhibit
activ
proteas
possibl
occupi
activ
site
pocket
addit
bromocriptin
along
type
interferon
exhibit
synergist
antizikv
activ
suramin
approv
drug
use
treat
trypanosom
human
sleep
sick
avail
prophylact
therapeut
use
children
inhibit
earli
step
zikv
bindingentri
decreas
number
infecti
zikv
progeni
virion
albulescu
et
al
tan
et
al
safe
pediatr
antiprotozoan
antivir
drug
nitazoxanid
found
affect
postattach
step
zikv
infect
dose
cao
et
al
antizikv
activ
nitazoxanid
less
niclosamid
poor
absorpt
niclosamid
might
reduc
util
hyperactiv
nmethyldaspart
receptor
nmdar
mediat
enhanc
glutam
releas
may
result
accumul
high
level
ca
neuron
may
lead
apoptosi
necrosi
neural
cell
neurodegener
zikv
diseas
possibl
occur
due
excitotox
glutam
fda
approv
nmdar
antagonist
drug
treat
alzheim
diseas
name
memantin
agmatin
ifenprodil
found
prevent
neuron
cell
death
caus
zikv
vitro
condit
without
reduc
viral
titer
costa
et
al
memantin
found
bind
noncompetit
nmdar
block
patholog
activ
nmdar
leav
physiolog
activ
unaffect
sirohi
kuhn
memantin
also
list
pregnanc
categori
b
drug
fda
henc
could
use
safe
reduc
neurolog
complic
associ
zikv
infect
sirohi
kuhn
practic
usag
repurpos
earlier
approv
drug
could
help
formul
fascin
approach
counter
zikv
associ
complic
purpos
research
work
need
move
clinic
trial
abil
zikv
infect
fetus
caus
sever
diseas
requir
develop
drug
function
pregnanc
safe
pregnant
mother
fetu
drug
must
abl
cross
placent
barrier
reach
fetu
cross
bloodbrain
barrier
reach
neural
cell
main
target
zikv
khandia
et
al
summar
fdaapprov
categori
b
drug
adequ
anim
studi
data
show
risk
fetus
control
studi
pregnant
women
unavail
categori
c
drug
anim
studi
reveal
teratogen
effect
fetus
control
studi
pregnant
women
unavail
howev
potenti
benefit
use
drug
may
outweigh
risk
list
contain
sever
drug
includ
fda
categori
b
drug
sofosbuvir
sacramento
et
al
azithromycin
retallack
et
al
niclosamid
palonosetron
pascoalino
et
al
mefloquin
balasubramanian
et
al
daptomycin
b
barrow
et
al
categori
c
drug
chloroquin
delvecchio
et
al
amodiaquin
quinacrin
hydrochlorid
balasubramanian
et
al
auranofin
clofazimin
deferasirox
methoxsalen
micafungin
sertralinehcl
fingolimod
ivermectin
digoxin
barrow
et
al
seliciclib
could
repurpos
treat
zikv
infect
recent
neutral
activ
human
convalesc
serum
zikv
demonstr
standard
plaqu
reduct
neutral
test
decreas
number
zikvinfect
brain
cell
icr
albino
fetal
mice
observ
treat
pregnant
mice
intraperiton
convalesc
serum
furthermor
zikvmedi
caspas
activ
reduc
indic
util
convalesc
serum
limit
zikv
infect
cell
death
convalesc
serum
also
revers
thin
cortic
plate
cp
ventricular
zone
vz
subventricular
zone
svz
observ
brain
zikvinfect
fetal
mice
therefor
use
convalesc
serum
treatment
zikvinfect
pregnant
women
whether
protect
brain
abnorm
fetus
assess
studi
wang
et
al
demonstr
suppress
zikv
infect
pregnant
mice
reduct
cell
use
convalesc
serum
high
amount
neutral
antibodi
convalesc
serum
also
inhibit
progenitor
cell
death
infect
fetal
brain
tissu
therebi
prevent
microcephali
zikvconfirm
convalesc
human
serum
abl
neutral
multipl
strain
infecti
zikv
zikv
rvp
indic
zikv
circul
singl
serotyp
wang
et
al
addit
antibodi
present
convalesc
serum
cross
placent
well
bloodbrain
barrier
fetus
thu
good
candid
treatment
infect
pregnant
women
convalesc
serum
free
zikv
bloodborn
pathogen
prior
transfer
therefor
heat
treatment
c
min
solventdeterg
sd
treatment
commonli
employ
sd
treatment
wtwt
trinbutyl
phosphat
tbp
wtwt
c
ph
min
complet
inactiv
zikv
et
al
photochem
amotosalen
quickli
intercal
dna
rna
strand
form
coval
adduct
pyrimidin
therebi
inhibit
replic
transcript
viru
plasma
sampl
treat
amotosalen
uvalight
safe
use
patient
free
viabl
zikv
particl
even
presenc
detect
amount
zikv
viral
rna
aubri
et
al
human
monoclon
mab
antibodi
denv
name
found
neutral
zikv
e
protein
use
electron
microscop
interact
studi
extracellular
ph
earli
ph
late
endosom
ph
stage
test
ph
bound
zikv
e
protein
differ
posit
ph
bound
intradim
interfac
ph
bound
viru
surfac
ph
block
raft
structur
note
differ
structur
rearrang
viru
block
antibodi
depict
visual
electron
microscop
suggest
broad
applic
differ
stage
infect
panel
human
mab
deriv
patient
previous
infect
zikv
mab
found
broadli
neutral
african
asianamerican
lineag
zikv
mab
recogn
uniqu
quaternari
epitop
e
protein
dimerdim
interfac
effect
reduc
zikv
infect
maternaltofet
transfer
tissu
patholog
mortal
sapparapu
et
al
threedimension
cryoelectron
microscopi
show
fab
crosslink
monom
surfac
e
glycoprotein
dimer
neighbor
dimer
therebi
prevent
structur
reorgan
e
protein
monom
requir
format
fusogen
e
protein
trimer
hasan
et
al
neutral
antibodi
target
highli
conserv
fusion
loop
region
flaviviru
e
protein
bind
high
affin
neutral
zikv
mous
model
moreov
human
mab
singl
zikv
patient
two
mab
potent
bound
neutral
zikv
cross
react
denv
strain
studi
regard
phenomenon
antibodydepend
enhanc
ade
viremia
increas
presenc
preexist
crossreact
poorli
neutral
antibodi
heterolog
flaviviru
strain
controversi
case
preexist
crossreact
antibodi
shown
increas
ade
experi
antibodi
exhibit
therapeut
potenti
instanc
preincub
human
myeloid
cell
poorli
permiss
zikv
convalesc
serum
obtain
subject
resolv
denv
infect
result
increas
zikv
infect
dejnirattisai
et
al
result
confirm
charl
christofferson
use
denv
serotyp
mab
demonstr
ade
zikv
infect
contradictori
find
report
pantoja
et
al
report
reduct
viremia
denvexpos
rhesu
macaqu
compar
anim
antibodi
wnv
also
shown
crossreact
zikv
e
protein
result
viremia
least
higher
control
studi
determin
role
antiwnv
antibodi
enhanc
zikv
reveal
pattern
like
observ
antidenv
antibodi
wnv
may
enhanc
zikv
vitro
well
vivo
howev
amplitud
enhanc
less
denv
bardina
et
al
wide
use
antiflaviviru
mab
possibl
use
mab
flavivirus
jev
yfv
limit
wnv
mediat
ade
zikv
consid
two
ediii
crossreact
mab
develop
zikv
denv
test
capac
ade
denv
zikv
infect
anim
model
mous
model
wildtyp
mab
without
lala
mutat
administ
prior
infect
result
sever
diseas
death
mice
day
postinfect
suggest
denv
infect
affect
presenc
preexist
zikv
antibodi
stettler
et
al
howev
antibodi
envelop
dimer
epitop
region
shown
neutral
zikv
addit
four
denv
serotyp
indic
potenti
immunetherapeut
potenti
zikv
infect
swanstrom
et
al
mous
mab
report
bind
conserv
motif
fl
loop
broadli
neutral
antibodi
neutral
also
protect
mice
zikv
infect
henc
seem
antigen
epitop
antibodi
gener
decid
factor
developingnot
develop
ade
epitop
result
poor
neutral
lead
ade
strongli
neutral
antibodi
therapeut
potenti
inform
regard
common
epitop
may
use
determin
strategi
limit
ade
develop
therapeut
mab
candid
lala
mutat
fc
region
antibodi
examin
figur
lala
mutat
leucin
l
toalanin
substitut
posit
lala
fc
region
igg
antibodi
bind
fc
region
antibodi
gamma
receptor
express
variou
immun
cell
trigger
effector
function
case
zikv
denv
virusantibodi
immun
complex
intern
result
ade
introduct
lala
mutat
fc
region
abolish
abil
bind
arduin
et
al
engin
antibodi
incap
interact
henc
elimin
ade
prior
denv
infect
vitro
vivo
william
et
al
antizikv
mab
lala
mutat
engin
therapeut
prophylact
purpos
ediiispecif
neutral
mab
lala
mutat
fc
region
block
ade
zikv
infect
cell
presenc
convalesc
serum
complet
protect
mice
lethal
zikv
challeng
administ
one
day
prior
post
challeng
stettler
et
al
given
high
potenc
vitro
vivo
efficaci
lala
mutant
neutral
antibodi
creation
mutant
appear
safe
promis
approach
inhibit
ade
patient
live
area
cocircul
flavivirus
lala
mutat
substitut
amino
acid
posit
fc
region
antibodi
reduc
bind
complement
thu
engin
antibodi
may
play
import
role
therapeut
prophylaxi
arduin
et
al
denv
human
mab
strongli
neutral
zikv
lala
mutat
introduc
induc
ade
show
reduc
viral
load
fetal
organ
prevent
virusinduc
fetal
growth
retard
indic
prophylact
potenti
antibodi
kam
et
al
addit
mab
mention
section
specif
neutral
zikv
neither
bind
neutral
four
denv
serotyp
also
great
import
limit
zikvassoci
ade
fact
patent
grant
baehner
et
al
modifi
fc
region
human
antibodi
reduc
affin
fold
result
inhibit
signal
cascad
lead
downstream
immun
respons
ade
case
denv
zikv
infect
herbal
drug
increas
interest
develop
antimicrobi
resist
microb
owe
cost
effect
curcumin
common
food
addit
abl
reduc
zikv
infect
hinder
viru
bind
host
cell
doseand
timedepend
manner
without
advers
effect
cellular
viabil
mounc
et
al
recent
chines
semisynthet
formul
andrographi
paniculata
name
xiyanp
combin
antivir
symptomat
treatment
administ
treat
zika
fever
patient
admit
ganxian
peopl
hospit
patient
recov
within
day
start
treatment
includ
medic
quercetin
flavonoid
present
fruit
veget
leav
grain
found
inhibit
zika
enzymat
activ
dosedepend
manner
commerci
avail
quercetin
report
inhibit
zikv
proteas
ic
vitro
studi
polyphenol
epigallocatechingal
egcg
found
green
tea
shown
inhibit
zikv
carneiro
et
al
structur
zikv
proteas
helicas
methyltransferas
gener
homolog
model
use
score
matrix
byler
et
al
molecular
dock
virtual
librari
phytochem
carri
plantderiv
secondari
metabolit
test
compound
dock
least
one
zikv
enzymat
protein
includ
balsacon
b
populu
balsamifera
kanzonol
v
glycyrrhiza
glabra
cinnamoylechinaxanthol
echinacea
cimiphenol
actaea
racemosa
rosemarin
receptor
present
surfac
variou
immun
cell
bind
antibodi
along
zikv
result
intern
immun
complex
cell
reduct
express
level
increas
level
act
autocrin
manner
bind
receptor
inhibit
jakstat
pathway
lead
reduc
product
reduc
ifnstimul
respons
element
product
result
decreas
nitric
oxid
product
nitric
oxid
diffus
radic
antimicrobi
antivir
reduc
result
increas
number
infecti
viru
particl
inhibit
diffus
cell
bind
receptor
reduc
jakstat
signal
b
antibodi
engin
prevent
ade
engin
antibodi
lala
mutat
fc
region
abl
neutral
viru
fail
bind
thu
prevent
ade
acid
rosmarinu
officinali
common
medicin
plant
may
serv
sourc
herbal
antivir
studi
encourag
find
structurebas
drug
byler
et
al
sever
bioactiv
compon
includ
alkaloid
flavonoid
saponin
tannin
terpenoid
essenti
oil
herb
azidarachta
indica
tinospora
cordifolia
shown
antiflavivir
activ
denv
jev
yfv
infect
antivir
agent
also
explor
efficaci
zikv
use
complementari
altern
medicin
parida
et
al
kiat
et
al
menes
et
al
tang
et
al
roy
et
al
ching
et
al
et
al
compound
use
treatment
variou
flavivir
diseas
readili
adapt
zikv
present
tabl
certain
compound
quinolin
coval
inhibitor
denv
act
inhibit
viral
e
protein
express
without
significantli
affect
host
housekeep
protein
gapdh
due
structur
similar
flavivir
e
protein
similar
compound
employ
combat
zikv
infect
de
wispelaer
et
al
host
caspas
found
mediat
lethal
multipl
pathogen
agent
base
hapmap
project
b
lymphoblastoid
cell
cohort
person
african
european
asian
ancestri
bithionol
fdaapprov
drug
inhibit
caspas
found
effect
reduc
neg
effect
zikv
bacteri
plant
toxin
thu
elucid
host
protein
diseas
use
design
drug
zikv
leonardi
et
al
nordihydroguaiaret
acid
ndga
alter
lipid
metabol
host
interven
sterol
regulatori
element
bind
protein
srebp
pathway
recent
inhibitor
srebp
pathway
includ
ndga
methyl
deriv
tetraomethyl
nordihydroguaiaret
n
fatostatin
also
found
reduc
wnv
zikv
replic
drug
candid
may
serv
effect
antivir
agent
zikv
merinoramo
et
al
zikv
bind
nerv
cell
tolllik
receptor
tlr
activ
lead
dysregul
gene
particip
neurogenesi
axon
guidanc
differenti
agonist
poli
c
thiophenecarboxamidopropion
compound
act
highaffin
competit
inhibitor
prevent
reduct
size
zikvtreat
neurospher
dang
et
al
metadichol
nanoemuls
policosanol
bind
vit
receptor
stimul
immun
system
displac
virus
bound
vit
receptor
therebi
block
viral
entri
host
cell
metadichol
shown
activ
zikv
ebov
sar
coronaviru
jev
wnv
yfv
sold
nutrit
supplement
asian
countri
well
toler
henc
use
safe
broadspectrum
antivir
agent
raghavan
similarli
test
broadspectrum
antivir
agent
antizikv
activ
aid
rapid
drug
discoveri
combat
viru
overview
recent
advanc
design
drug
therapi
zikv
present
tabl
recent
therapi
includ
cytokin
tlr
sirna
rna
interfer
probiot
immunomodulatori
intervent
nanodrug
deliveri
approach
gain
momentum
examin
optimum
benefit
safeti
human
companion
anim
prospect
aspect
valuabl
therapi
could
given
due
focu
design
develop
effect
drug
medicin
therapeut
immunomodulatori
pharmaceut
treatment
zikv
infect
molecular
genet
analys
indepth
understand
zikv
pathogenesi
would
facilit
identif
novel
target
develop
safer
effect
drug
counter
zikv
effect
zika
viru
arboviru
share
sever
characterist
featur
member
flaviviru
famili
recent
evid
autoimmun
complic
gb
maternaltofet
transmiss
viru
lead
microcephali
accumul
use
stateoftheart
method
formul
effect
diagnost
antivir
drug
therapeut
vaccin
prevent
control
strategi
would
aid
address
emerg
viru
recent
therapi
shown
promis
inhibit
zikv
infect
associ
diseas
therapi
includ
limit
viral
entri
cell
target
zikv
helicas
protein
use
nucleosid
analog
like
cmethyl
nucleosid
cmethyladenosin
termin
nascent
rna
strand
format
use
antibodi
bind
zikv
neutral
reduc
risk
ade
ade
major
concern
applic
zikv
therapi
geograph
region
flavivirus
endem
thu
limit
ade
antibodi
engin
contain
modifi
fc
region
modif
fc
region
antibodi
hamper
attach
inhibit
intern
immun
complex
also
reduc
complement
bind
prevent
ade
futur
sever
mutat
may
identifi
human
mab
genet
engin
prevent
ade
combin
use
engin
antibodi
might
evalu
synergist
effect
therapeut
prophylact
regimen
encourag
result
repurpos
drug
shown
use
chloroquin
malaria
drug
led
screen
sever
fdaapprov
drug
includ
niclosamid
emricasan
daptomycin
palonosetron
kitasamycin
mani
zikv
treatment
anoth
valuabl
strategi
discoveri
zikv
prevent
antivir
use
comput
analysi
insight
genet
molecular
mechan
associ
recent
increas
virul
zikv
could
aid
design
develop
safer
potent
drug
therapeut
zikv
along
identifi
novel
drug
target
therapeut
vaccin
strengthen
appropri
prevent
control
measur
includ
mosquito
control
could
help
limit
zikv
infect
associ
complic
potenti
spread
time
research
pharmaceut
compani
polici
maker
regul
fund
agenc
identifi
implement
strategi
counter
zikv
global
sinc
declar
zika
epidem
intern
public
health
emerg
research
zikv
increas
mani
fold
howev
area
still
need
address
percent
contribut
rout
zikv
infect
precis
understood
present
base
mathemat
model
studi
sexual
transmiss
estim
account
upto
transmiss
contribut
rout
infect
yet
studi
knowledg
may
help
design
precis
target
inhibitori
molecul
block
infect
site
entri
mani
fda
approv
drug
test
efficaci
zikv
repurpos
treat
zikv
infect
human
howev
date
fda
categori
drug
identifi
clinic
safe
use
mother
fetus
engin
mab
two
mutat
prevent
intern
immun
complex
ie
lala
substitut
identifi
mutat
must
identifi
optim
efficaci
synerg
author
substanti
contribut
concept
design
analysi
interpret
data
check
approv
final
version
manuscript
agre
account
content
rk
initi
review
compil
kd
review
analyz
edit
rk
design
tabl
rk
kk
design
figur
ss
rt
cover
critic
aspect
drug
vaccin
develop
ym
rs
review
virolog
aspect
analyz
data
dk
review
biotechnolog
bioinformat
advanc
hi
sk
overview
immunotherapeut
aspect
drug
develop
author
acknowledg
thank
respect
institut
univers
